![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
针对BCMA的CAR T细胞疗法可以有效地诱导耐性狼性炎的疾病缓解
Ziwei Hu1, Shaozhe Cai1, Yikai Yu1
1Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Annals of the rheumatic diseases
|July 18, 2025
概括
抗BCMA CAR T细胞疗法对狼性炎 (LN) 的治疗有希望. 这种治疗通过向B细胞,在大多数患者中安全地诱导缓解,为自身免疫性疾病提供了一种新方法.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞疗法细胞疗法
- 自免疫性疾病 自免疫性疾病
背景情况:
- 耐火性狼性炎 (LN) 带来了重大的治疗挑战.
- 针对自身免疫性疾病的B细胞向疗法正在探索中.
研究的目的:
- 评估抗BCMA化学抗原受体 (CAR) T细胞在耐火性LN患者中的安全性和有效性.
- 评估在自身免疫性疾病中向B细胞成熟抗原 (BCMA) 的治疗潜力.
主要方法:
- 一个开放的,单臂的临床试验,涉及淋巴细胞减少后的抗BCMA CAR T细胞输液.
- 进行了定期的临床评估,实验室监测和重复的单细胞RNA测序脏活检.
- 主要终点包括安全剂量和不良事件;次要终点侧重于疗效,如SLEDAI-2000分数.
主要成果:
- 七名LN患者接受治疗,随访时间中位数为9个月.
- 观察到有效的B细胞枯竭,在大多数患者中在3个月内恢复;低二球蛋白血症是常见的.
- 5/7患者的SLEDAI-2000分数显著降低和DORIS完全缓解,由脏活检和转录组数据支持.
结论:
- 抗BCMA CAR T细胞疗法是一种安全有效的治疗方法,用于诱导和维持狼性炎的缓解.
- 这种针对BCMA的策略证明了治疗异常 humoral 免疫的自身免疫性疾病的可行性.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664